This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Thursday's Health Winners & Losers

Shares of specialty pharmaceutical company A.P. Pharma (APPA) plummeted after the company said it will probably miss its target date for a new drug application.

The company previously expected to file its Food and Drug Administration application for APF530 -- which treats chemotherapy-induced nausea and vomiting -- in 2007. However, due to lower-than-expected patient enrollment rates, the company is unlikely to reach that goal. The stock sank 16.7% to $1.25.

Shares of Repros Therapeutics (RPRX) jumped 10.5% to $7.69 after the company announced positive trial results on Proellex, a proposed treatment for uterine fibroid symptoms. Early study results showed that use of the drug led to a highly significant reduction in pain and excessive bleeding related to the noncancerous tumors and helped improve overall quality of life when compared with a placebo.

Depomed (DEPO - Get Report) shares gained 3.8% to $3.26 after the company announced a favorable decision from a California court on the company's patent infringement case against Ivax. The patents cover a drug delivery technology used in Depomed's diabetes drug Glumetza.

Shares of Accentia Biopharmaceuticals (ABPI) were up 31.8% to $4.27 after the company said it entered mutual confidentiality agreements with several respiratory care companies. The companies have approached Accentia regarding its experimental drug SinuNase for the treatment of chronic sinusitis. The company says partnerships could provide upfront and milestone payments and enhance sales and marketing opportunities.

Among other health stock winners were Sepracor (SEPR), gaining 6.7% to $61.19; Dr. Reddy's Laboratories (RDY - Get Report), 1.4% higher to $17.87; Entremed (ENMD), up 4.2% to $1.73; Memory Pharmaceuticals (MEMY), rising 9.9% to $2.34; and Gilead Sciences (GILD), 1.2% higher to $65.54.

Losers included Somaxon Pharmaceuticals (SOMX), down 11.1% to $13.19; Avanir Pharmaceuticals (AVNR), falling 9% to $2.32; Gentium (GENT) 3.7% lower to $20.95; Neurochem (NRMX), losing 4% to $22.77; and Dade Behring (DADE), off 1% to $40.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
ABPI $0.00 3.45%
APPA $13.07 0.46%
DEPO $22.67 3.66%
RPRX $8.57 0.12%
RDY $54.50 0.81%


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs